Cellectar Biosciences (CLRB) Non Operating Income (2010 - 2026)
Cellectar Biosciences (CLRB) posted Non Operating Income of -$358299.0 for Q4 2025, down 188.07% sequentially from $406819.0 in Q3 2025, and down 108.14% YoY from $4.4 million in Q4 2024.
Cellectar Biosciences (CLRB) Non Operating Income (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Non Operating Income for 16 years, with the latest figure at -$358299.0 in Q4 2025.
- Quarterly Non Operating Income fell 108.14% year-over-year to -$358299.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $435100.0 (down 97.31% YoY) and the FY2025 annual result came in at $435100.0, down 64.07% from the prior year.
- Non Operating Income retreated to -$358299.0 in Q4 2025 per CLRB's latest filing, from $406819.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $12.8 million in Q2 2024 and troughed at -$8.1 million in Q3 2023.
- A 5-year average of $171943.4 and a median of $1510.5 in 2021 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 51453.22% in 2022, then plunged 391916.63% in 2023.
- Over 5 years, Non Operating Income stood at $5307.0 in 2021, then tumbled by 95142.77% to -$5.0 million in 2022, then surged by 102.76% to $139222.0 in 2023, then jumped by 3063.33% to $4.4 million in 2024, then slumped by 108.14% to -$358299.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$358299.0, $406819.0, and $589618.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | 265,359.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 265,359.00 |
| Dec 31, 2025 | -358,299.00 |
| Sep 30, 2025 | 406,819.00 |
| Jun 30, 2025 | 589,618.00 |
| Mar 31, 2025 | -203,038.00 |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | -1.34 Mn |
| Jun 30, 2024 | 12.78 Mn |
| Mar 31, 2024 | 319,849.00 |
| Dec 31, 2023 | 139,222.00 |
| Sep 30, 2023 | -8.11 Mn |
| Jun 30, 2023 | -1.88 Mn |
| Mar 31, 2023 | 1.51 Mn |
| Dec 31, 2022 | -5.04 Mn |
| Sep 30, 2022 | 304,164.00 |
| Jun 30, 2022 | 481.00 |
| Mar 31, 2022 | -99,570.00 |
| Dec 31, 2021 | 5,307.00 |
| Sep 30, 2021 | 590.00 |
| Jun 30, 2021 | 659.00 |